Key Highlights

  • First ISEMBYLD product Revenue was USD 0.6 million in the third quarter, reflecting initial inventory shipped to the specialty network, after FDA approval on September 11, 2026 and no revenue in the prior-year period.
  • The net loss was USD 107.2 million, or USD 0.81 per share, compared with USD 102.2 million a year earlier, as Research and Development rose 7.2% to USD 54.1 million.
  • Cash, cash equivalents and marketable securities totaled USD 413.6 million at September 30, 2026, up from USD 367.6 million at the end of 2025.
  • The company agreed in November 2026 to sell its priority review voucher for USD 205.0 million in cash, subject to customary closing conditions.

First Launch Revenue Arrives After the September Approval

Scholar Rock (NASDAQ:SRRK) filed its Quarterly Report and held its call on November 10, 2026. Net product revenue was USD 0.6 million, all from ISEMBYLD, the first muscle-targeted therapy approved for spinal muscular atrophy patients aged two and older who already receive an SMN2-targeted treatment. Cost of product revenue was only USD 8,000 because the filing says USD 25.6 million of related inventory was expensed before approval. Management said the early pace of patient enrollments has been steady and balanced across geographies, but that Demand is outpacing reimbursement, with most patients enrolled through October expected to begin infusions in 2027. Management estimates about 6,600 U.S. patients receive an SMN2-targeted therapy, and said Anthem and Centene have published policies in line with the label.

Losses Widen Slightly While the Balance Sheet Gets a USD 205 Million Boost

Total operating expenses were USD 106.6 million, up 3.0%, with selling, general and administrative expense of USD 52.5 million, down 1.1%. Management said operating expenses included USD 17.9 million of non-cash stock compensation. The nine-month net loss was USD 322.6 million and the accumulated Deficit stood at USD 1.6 billion. Cash and marketable securities were USD 413.6 million, and the company said the voucher sale to BioNTech US, expected to add USD 205.0 million on closing, plus access to another USD 150 million under its Debt facility, mean it does not need an Equity offering at this time.

Europe and Japan Filings Set the Next Regulatory Clock

Management said it resubmitted its European Marketing application in October 2026 and expects a CHMP opinion in the first half of 2027. It also submitted a Japanese application in early November, accepted under priority review, with a launch anticipated near year-end 2027. The company applied for an ISEMBYLD-specific J-code, which management said would take effect on April 1. Risks listed in the filing include near-term dependence on a single approved product, limited commercial experience, delayed European progress, and uncertain pricing and reimbursement in the EU, plus continued losses as launch spending grows.

Where Things Stand

Possibly, but the voucher sale is a funding bridge rather than a profit driver. Scholar Rock (NASDAQ:SRRK) ended the quarter with USD 413.6 million, and the USD 205.0 million sale would add to that once it closes. Revenue is still tiny at USD 0.6 million against a USD 107.2 million quarterly loss. The USD 107.2 million loss and rising launch costs mean the cash cushion will be tested over time. Next markers are the sale closing, the pace of payer approvals and first infusions in 2027, the CHMP opinion in the first half of 2027, and the Japan decision. The next quarterly report will show how much of the enrolled demand turns into revenue.